The ASH Annual Meeting and Exposition took place December 9–12, 2023 in San Diego, California, USA, welcoming expert hematologists and other healthcare professionals from around the world. This year’s ASH meeting had record-breaking attendance, with approximately 32,000 in-person and 5000, virtual attendees. The ASH 2023 program was comprehensive and covered key areas of discussion and scientific developments related to both nonmalignant and malignant hematology. The rich program offered the opportunity for attendees to engage, discuss, and understand the latest and greatest science informing both current and future clinical practice in their fields.
In this highlights report, we focus on the key data and discussion topics related to hematologic malignancy. Key topics included potentially practice‑changing clinical trial results; new developments in CAR T‑cell therapies; exciting data for bi and trispecific monoclonal antibodies; the value of measurable residual disease assessments; and the place of AI in clinical practice. We will focus on these topics on the following pages.
A team of our OPEN Health hematology experts were present for the duration of the meeting, attending a variety of sessions and getting the most out of this excellent opportunity to learn both from and along with the experts. The attending delegates participated in engaging discussions during these sessions, with thoughtful questions aimed at helping to contextualize new data and understand their impact on current clinical practice. Discussions also identified areas of focus for future research. The energy at ASH was palpable in person and on social media, on which attendees shared the most exciting research from this dynamic conference (#ASH23).
This insights report will be used to unlock possibilities in our future work. Please get in touch if you would like to hear more about this year’s ASH proceedings and their implications for your Medical Affairs strategy development and medical communications planning.
- Cindy Gobbel, PhD, Senior Medical Director, Scientific Communications
